Table 3.
Comparison of risk factors between Anti-N-Ab+ and Ant-N-Ab- subgroups among male, female and total subjects.
| Variables | Male, n = 108 n (%) |
p-value | Female, n = 159 n (%) |
p value | Total,n = 267 n (%) |
p-value | |||
|---|---|---|---|---|---|---|---|---|---|
| Ab + ve (n = 56) | Ab-ve (n = 52) | Ab + ve (n = 79) | Ab-ve (n = 80) | Ab + ve (n = 135) | Ab-ve (n = 132) | ||||
| Age (in years), Median (Range) |
42 (23–60) | 40 (21–60) | 0.51 | 34 (23–60) | 35 (23–65) | 0.61 | 38 (23–60) | 37 (21–65) | 0.40 |
| Age (Category) | |||||||||
| 21–40 | 25 (44.64) | 26 (50) | 0.83 | 45 (56.96) | 48 (60) | 0.14 | 70 (51.85) | 74 (56.06) | 0.21 |
| 40–50 | 11(19.64) | 10 (19.23) | 10 (12.65) | 17 (21.25) | 21 (15.55) | 27 (20.45) | |||
| >50 | 20 (35.71) | 16 (30.76) | 24 (30.37) | 15 (18.75) | 44 (32.59) | 31 (23.48) | |||
| BMI, Median (Range) | 26 (15–39) | 26 (16–41) | 0.30 | 24 (16–42) | 24 (15–49) | 0.57 | 25 (15–42) | 25 (15–49) | 0.45 |
| BMI category | |||||||||
| <18.5 | 2 (3.57) | 3 (5.76) | 0.83 | 9 (11.39) | 7 (8.75) | 0.70 | 11 (8.14) | 10 (7.57) | 0.84 |
| <18.5–22.9 | 8 (14.28) | 5 (9.61) | 24 (30.37) | 21 (26.25) | 32 (23.70) | 26 (19.69) | |||
| 23–27.5 | 25 (44.64) | 25 (48.07) | 31 (39.24) | 31 (38.75) | 56 (41.48) | 56 (42.42) | |||
| >27.5 | 21 (37.5) | 19 (36.53) | 15 (18.98) | 21 (26.25) | 36 (26.66) | 40 (30.30) | |||
| WHR, Median (Range) | 0.94 (0.74–1.17) | 0.96 (0.82–1.13) | 0.07 | 0.89 (0.67–1.21) | 0.90 (0.68–1.06) | 0.74 | 0.91 (0.46–1.21) | 0.92 (0.68–1.13) | 0.27 |
| WHR category | |||||||||
| Low WHR (<0.95, M; <0.80, F) | 36 (64.28) | 25 (48.07) | 0.10 | 12 (15.18) | 10 (12.5) | 0.88 | 48 (35.55) | 35 (26.51) | 0.42 |
| Normal WHR (0.96–1.0, M; 0.81–0.85, F) | 8 (14.28) | 6 (11.53) | 14 (17.72) | 15 (18.75) | 22 (16.29) | 21(15.90) | |||
| High (WHR >1.0, M; >0.85, F | 12 (21.42) | 21(40.38) | 53 (67.08) | 55 (68.7) | 65 (48.14 | 76 (57.57) | |||
| COVID symptom anytime + ve | 44 (78.57) | 35 (67.31) | 0.20 | 42 (53.16) | 37 (46.25) | 0.75 | 86 (63.7) | 49 (37.12) | 0.62 |
| Covid Symptom anytime -ve | 12 (21.43) | 17 (32.69) | 45 (56.96) | 35 (43.75) | 80 (59.26) | 52 (39.39) | |||
| Covid Symptom last 3 months + ve | 9 (16.07) | 47 (90.38) | 0.02 | 19 (24.05) | 60 (75) | 0.05 | 28 (20.78) | 107 (81.06) | 0.04 |
| Covid Symptom last 3 months -ve | 1 (1.78) | 51 (9.07) | 15 (18.98) | 65 (81.25) | 16 (11.85) | 116 (87.87) | |||
| Covid rtPCR anytime + ve | 20 (35.71) | 36 (69.23) | 0.84 | 26 (32.91) | 53 (66.25) | 0.22 | 46 (34.07) | 89 (67.42) | 0.24 |
| Covid rtPCR anytime -ve | 17 (30.36) | 35 (67.31) | 19 (24.05) | 61 (76.25) | 36 (26.66) | 96 (72.72) | |||
| Covid rtPCR last 3 months + ve | 17 (30.35) | 39 (75.00) | 0.83 | 6 (7.59) | 73 (91.25) | 0.32 | 10 (7.41) | 125 (94.69) | 0.17 |
| Covid rtPCR last 3 months -ve | 14 (25.00) | 38 (73.00) | 3 (3.79) | 77 (96.25) | 4 (2.69) | 128 (96.96) | |||
| Any Comorbidity + ve | 15 (26.78) | 41 (78.85) | 0.31 | 31 (39.24) | 48 (60) | 0.62 | 46 (34.07) | 89 (67.42) | 0.79 |
| Any Comorbidity -ve | 19 (32.93) | 33 (63.46) | 28 (35.44) | 52 (65) | 47 (34.81) | 85 (64.39) | |||
| Diabetes + ve | 5 (8.93) | 51 (98.08) | 0.17 | 14 (17.72) | 65 (81.25) | 0.84 | 19 (14.07) | 116 (87.87) | 0.50 |
| Diabetes -ve | 10 (17.86) | 42 (80.76) | 13 (16.45) | 67 (83.75) | 23 (17.04) | 109 (82.57) | |||
| Hypertension + ve | 7 (12.5) | 49 (94.23) | 0.30 | 17 (21.52) | 62 (77.5) | 0.55 | 24 (17.77) | 111 (84.09) | 0.88 |
| Hypertension -ve | 11 (19.64) | 41 (78.85) | 14 (17.72) | 66 (82.5) | 25 (85.52) | 107 (81.06) | |||
Data were expressed as n (%) or median (range) as appropriate. Chi-square and Mann-Whitney tests were used to find out the association between categorical and continuous variables, respectively. P < 0.05 was considered as significant.